Accessibility Menu
Neuronetics logo

Neuronetics(NASDAQ) STIM

Current Price$1.93
Market Cap$134.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-93%
5 Year-86%
1 Year-54%
1 Month+61%
Neuronetics last closing stock price
MetricPriceDate
Last closeUSD 1.932026-07-22
Neuronetics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.89%USD 1.842026-07-15
1 month+60.83%USD 1.202026-06-22
3 month+14.2%USD 1.692026-04-23
Year to date+39.86%USD 1.382025-12-31
1 year-54.27%USD 4.222025-07-22
3 year-6.31%USD 2.062023-07-21
5 year-85.7%USD 13.502021-07-23
Since inception-93.23%USD 27.782018-06-28

Neuronetics Financials at a Glance

Market Cap

$134.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$151.64M

Net Income (TTM)

-$37.11M

EPS (TTM)

-$0.55

P/E Ratio

-3.53

Dividend

$0.00

Beta (Volatility)

1.42 (Average)

Price

$1.93

Volume

825,122.168

Open

$1.88

Previous Close

$1.93

Daily Range

$1.84 - $1.94

52-Week Range

$0.80 - $4.85

Estimated Earnings Date

Aug 4, 2026

STIM News

Medical pro holding dollar sign paperweight

Why Neuronetics Blasted 39% Higher Today

Eric VolkmanMay 4, 2021

STIM: Motley Fool Moneyball Superscore

49

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neuronetics

Neuronetics helps adults with depression who do not respond to medication. Its main device uses magnetic pulses to stimulate brain areas linked to mood. The company also runs clinics offering in-person treatments for mental health conditions.

Products and Services

  • NeuroStar Advanced Therapy System: Non-invasive device for treating depression; 10% of 2025 U.S. revenue.
  • Treatment Sessions: Single-use codes for each therapy session; 30% of 2025 U.S. revenue.
  • Greenbrook Clinics: In-person centers for depression therapies; 59% of 2025 U.S. revenue.
  • SPRAVATO Therapy: Esketamine nasal spray for resistant depression, offered at 83 clinics.
  • Practice Support: Training, reimbursement help, and management software for clinics and psychiatrists.

Growth and Expansion

  • Acquired Greenbrook in December 2024, adding 93 clinics and direct patient care.
  • Expanded SPRAVATO therapy to 83 clinics in 2025.
  • Launched new payment models and leasing options for devices in 2025.
  • Entered Japan market with exclusive distribution agreement through March 2027.
  • Increased research and development for new uses of its main device.

What Makes Neuronetics Stand Out

Neuronetics combines device manufacturing with direct patient care, controlling both product and service delivery. Its clinics and device network reach 15 U.S. states and select international markets. The company supports clinics with training, reimbursement help, and cloud-based management tools.

Five Things You Need to Know

  • Revenue was $149.2 million in 2025, up 99% from 2024.
  • Clinic revenue made up 59% of U.S. revenue in 2025, up from 6% in 2024.
  • Gross margin fell to 48.5% in 2025, down from 72.3% in 2024.
  • Net loss was $39.1 million in 2025, improved from $43.7 million in 2024.
  • Cash used in operations was $20.4 million in 2025, down from $31.0 million in 2024.

Bottom Line

Neuronetics has shifted from device sales to a clinic-based model after acquiring Greenbrook. The company now combines technology, direct care, and support services for mental health treatment.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

658

CEO

Daniel L. Reuvers

Website

www.neurostar.com

Headquarters

Malvern, PA 19355, US

STIM Financials

Key Financial Metrics (TTM)

Gross Margin

47.96%

Operating Margin

-19.40%

Net Income Margin

-24.48%

Return on Equity

-164.68%

Return on Capital

-27.90%

Return on Assets

-29.59%

Earnings Yield

-28.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$134.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

69.59M

Volume

825.12K

Avg. Volume

2.28M

Financials (TTM)

Gross Profit

$72.72M

Operating Income

-$29.42M

EBITDA

-$25.70M

Operating Cash Flow

-$12.80M

Capital Expenditure

-$779.00K

Free Cash Flow

-$13.58M

Cash & ST Invst.

$13.21M

Total Debt

$85.39M

Neuronetics Performance Analysis

Neuronetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 65,206,00017.9%
20232023-12-31USD 71,348,0009.4%
20242024-12-31USD 74,890,0005.0%
20252025-12-31USD 149,157,00099.2%
Neuronetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3019.2%
Q32025-09-30-2.1%
Q42025-12-3112.0%
Q12026-03-31-17.5%
Neuronetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3812.8%
20232023-12-31USD -1.05-23.7%
20242024-12-31USD -1.3830.7%
20252025-12-31USD -0.59-57.1%
Neuronetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3028.6%
Q32025-09-3013.3%
Q42025-12-3123.1%
Q12026-03-31-60.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$34.45M

+7.8%

Gross Profit

$16.15M

+2.6%

Gross Margin

46.89%

N/A

Market Cap

$134.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$204.11K

N/A

Employees

658

N/A

Net Income

-$10.79M

+14.9%

EBITDA

-$7.78M

+21.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$13.21M

-38.3%

Total Debt

$85.39M

+3.5%

Accounts Receivable

$16.07M

-40.3%

Inventory

$4.72M

+15.9%

Long Term Debt

$79.97M

+3.0%

Short Term Debt

$5.42M

+10.2%

Return on Assets

-29.59%

N/A

Return on Invested Capital

-30.28%

N/A

Free Cash Flow

-$9.62M

+44.1%

Operating Cash Flow

-$9.42M

+44.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CDXSCodexis, Inc.
$2.06-6.36%
ATLNAtlantic International Corp.
$0.90+0.00%
NYXHNyxoah S.A.
$1.53-0.65%
PROFProfound Medical Corp.
$6.99+1.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%
NUNu Holdings
$14.51+0.01%

Questions About STIM

What is the current price of Neuronetics?

Neuronetics is trading at $1.93 per share.

What is the 52-week range for Neuronetics?

Over the past 52 weeks, Neuronetics has traded between $0.80 and $4.85.

How much debt does Neuronetics have?

As of the most recent reporting period, Neuronetics reported total debt of $85.39M.

How much cash does Neuronetics have on hand?

Neuronetics reported $18.96M in cash and cash equivalents in its most recent financial results.

What is Neuronetics’s dividend yield?

Neuronetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services